June 18, 2020 -- Codagenix has successfully synthesized a live-attenuated vaccine candidate for COVID-19 called CDX-005.
The vaccine candidate is undergoing safety and efficacy studies in animals, according to the firm, which expects to have preclinical data by early July. Once preclinical trials are complete, CDX-005 will be tested in a phase I trial in the fall, according to the firm.
CDX-005 is one of the few vaccine candidates currently under development using the live-attenuated approach, which mimics SARS-CoV-2.
The company is collaborating with the Serum Institute of India to develop CDX-005 which will conduct the phase I clinical trial in the fall. The compound grows rapidly in cell culture, which means that it can be produced quickly, Codagenix said.
Copyright © 2020 scienceboard.net